Monoclonal antibodies against BCMA

Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy

Bispecific IgG antibodies as T cell engagers

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME

Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex

Folate receptor 1 antibodies and immunoconjugates and uses thereof

TARGETED T CELLS WITH CYTOTOXICITY TOWARD IMMUNOSUPPRESSIVE CELLS

Therapeutic agents targeting CLPTM1

Anti-B7-H1 antibodies for treating tumors

CELL DEATH INDUCING CHIMERIC ANTIGEN RECEPTORS

CHIMERIC ANTIGEN RECEPTOR AND NATURAL KILLER CELLS EXPRESSING SAME

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

Anti-FGFR3 antibodies and methods using same

CMET monoclonal binding agents, drug conjugates thereof and uses thereof

IGF-1R antibody and its use as addressing vehicle for the treatment of cancer

Anti-human VISTA antibodies and use thereof

Anti-ICOS antibodies

LAG-3 binding members

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses

Chimeric antigen receptors based on alternative signal 1 domains

METHOD FOR PURIFYING ANTIBODIES USING PBS

Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND METHODS OF MAKING AND USING SAME

Anti-CD25 antibody agents

Agonistic antibodies that bind CD40

Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders

Anti-Psl binding molecules and uses thereof

Affinity maturated TAG72 specific single chain antibodies

HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR

Anti-DR5 antibodies and methods of use thereof

Targeting agent antibody conjugates and uses thereof

METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS

Humanized and affinity matured antibodies to FcRH5 and methods of use

Antibody agents specific for human CD19 and uses thereof

Treatment of peripheral T cell lymphoma

Therapeutic DLL4 Binding Proteins

Anti-complement factor H antibodies

Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms

Compositions and methods to treat solid tumors

PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

Anti-TREM2 antibodies and related methods

CELL PENETRATING NUCLEOLYTIC ANTIBODY BASED CANCER THERAPY

Chimeric antigen receptor and CAR-T cells that bind BCMA

Polyglutamated antifolates and uses thereof

Anti-PSMA antibodies, uses thereof and conjugates thereof

Engineered CD46-specific effector cells and uses thereof in the treatment of cancer

ANTI-CD27 ANTIBODIES

ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF

Anti-CD25 antibody agents

Therapeutic CD47 antibodies

Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer

IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof

ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF

NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS

HUMANIZED ANTI-MUC1* ANTIBODIES AND USE OF CLEAVAGE ENZYME

Heterodimeric immunoglobulin constructs and preparation methods thereof

Anti-CD25 antibody agents

Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof

BISPECIFIC ANTIBODY BINDING TO HUMAN CD19 AND CD3

Humanized or chimeric CD3 antibodies

Anti-KRAS binding proteins

T cell receptor-like antibodies specific for Foxp3-derived peptides

IL2 and TNF immunoconjugates

Peptide-DNA chimeras for treatment of HER overexpressing cancers

CCR3 inhibition for ocular angiogenesis and macular degeneration

HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Bifunctional polypeptides

Antibodies to CD70

Integrin alpha 9 blockade suppresses lymphatic valve formation and promotes transplant survival

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

Methods of treating an IGFBP-3R expressing cancer using anti-IGFBP-3R antibodies

IL-6 antibodies and fusion constructs and conjugates thereof

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Antibodies directed to HER-3 and uses thereof

CD20 antibodies

Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

Cysteine engineered fibronectin type III domain binding molecules

Antibody constructs for DLL3 and CD3

Antibody binding specifically to CD66c and use thereof

CD3 binding antibodies

METHODS OF MODULATING PLEXIN B2 ACTIVITY

Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof

Glucocorticoid receptor agonist and immunoconjugates thereof

Monoclonal antibodies prevent cell surface protein shedding and block tumor growth

Anti-CD73 antibodies and uses thereof

Human antibody κ type light chain complex-containing composition and method for producing same

Compositions and methods for TCR reprogramming using fusion proteins

Interferon Therapy

Chemically-locked bispecific antibodies

Antibodies binding to HLA-A2/WT1

Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases

Nucleic acids encoding an anti-CD40 antibody

Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies

Mixtures of antibodies

Heterodimeric antibodies that bind somatostatin receptor 2

Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs

Therapeutic CD47 antibodies

Drug regulated transgene expression

BSL2v2c2-Ig polypeptides

Antibody/T-cell receptor chimeric constructs and uses thereof

DLL3 MODULATORS AND METHODS OF USE

Anti-PD-L1-anti-TIM-3 bispecific antibodies

Anti-MERTK agonistic antibodies and uses thereof

HER-2 binding antibodies

Monoclonal antibody and a method of use for the treatment of lupus

Chimeric antigen receptors targeting B-cell maturation antigen

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance

Anti-B7-H4 antibodies and immunoconjugates

BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123

Compositions And Methods For Treating Angiogenesis-Related Disorders

Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)

Adenovirus armed with bispecific T cell engager

MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER

Single-domain antibodies and variants thereof against CTLA-4

IL-6 binding molecules

Fusion proteins for treating cancer and related methods

Bifunctional polypeptides

Bifunctional polypeptides

Vaccine composition comprising cyclic peptides, antibodies to the cyclic peptides or an anticancer composition comprising the same

Combination therapy with glutaminase inhibitors and immuno-oncology agents

INNATE IMMUNE CELL TRISPECIFIC BINDING PROTEINS AND METHODS OF USE

Anti-IGF antibodies

Alpha polyglutamated antifolates and uses thereof

Human antibody specifically binding to acne bacteria using phage display technique, and use thereof

CD37-binding molecules and immunoconjugates thereof

Compositions for achieving therapeutically effective doses of anti-CD47 agents

Immunoglobulin constant region Fc receptor binding agents

COMPOSITIONS FOR AND METHODS OF TREATING AND PREVENTING CANCER TARGETING TUMOR ASSOCIATED CARBOHYDRATE ANTIGENS

Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer

METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES

BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR

Treatment of breast cancer brain metastases

Human CD3 binding antibody

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Heterodimeric antibodies that bind CD3 and tumor antigens

Cys80 conjugated immunoglobulins

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

EphA5-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies

EGFR binding molecules

Antibodies against Frizzled receptor

ANTIBODY VARIANTS

Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager

Antibody to Renalase

Antigen binding protein against HER3

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

ANTI-SAS1B ANTIBODIES, ASSOCIATED METHODS OF USE, AND COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER

Anti-BAFFR antibody formulations and methods of use thereof

Antibodies specific for epidermal growth factor receptor variant III and their uses

Anti-nucleolin antibodies

Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients

Anti-TNF-alpha-antibodies and functional fragments thereof

Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof

Methods for the depletion of cells

Antibody directed against the endothelin receptor beta sub-type

Binding molecules with modified J-chain

Targeting CLPTM1L for treatment and prevention of cancer

ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID

Anti-HER2 antibodies and immunoconjugates

Multispecific antibodies

Anti-fibulin-3 antibodies and uses thereof

Anti-Axl antagonistic antibodies

Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof

Anti-C10ORF54 antibodies and uses thereof

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

Chimeric antigen receptor

Antibodies to TGF-β

Anti-annexin A2 monoclonal antibodies

Compositions and methods for using albumin-based nanomedicines

CANCER AND B-CELL RELATED DISEASE THERAPY

Anti-CD40 antibodies

Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer

Optimized PNE-based chimeric receptor T cell switches and uses thereof

Modified anti-tenascin antibodies and methods of use

Constructs having a SIRP-alpha domain or variant thereof

T cell receptors and uses thereof

Compositions and methods for inducing apoptosis

Therapeutic combinations comprising anti-FOLR1 immunoconjugates

Fusion protein construct

Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Antibodies specific to Sonic Hedgehog and method of use thereof

Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)

MRNA display antibody library and methods

Antibody having improved stability and specifically binding to HER2

Antibody binding to carbonic anhydrase and use thereof

Chimeric polypeptide assembly and methods of making and using the same

Compositions and methods for the depletion of CD117+ cells

Anti-LAG-3 antibodies

Chimeric antigen receptors and uses thereof

Bispecific antibodies targeting EGFR and HER2

Treatment of eosinophil or mast cell related disorders

Anti-ROR1 antibodies

Anti-TNFα-antibodies and functional fragments thereof

ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR

METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS

Antibodies, uses thereof and conjugates thereof

Compositions and methods for the depletion of CD117+ cells

Antagonistic anti-tumor necrosis factor receptor 2 antibodies

ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF

Chimeric antigen receptors targeting epidermal growth factor receptor variant III

ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS

PD-L1 Antibodies

Anti-PD-1 antibodies and uses thereof

Antibodies specific to delta 1 chain of T cell receptor

Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies

GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME

Bispecific antibodies for use in stem cell transplantation

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

Treatment of cancer using humanized anti-CD19 chimeric antigen receptor

Anti-CSPG4 fusions with interferon for the treatment of malignancy

CD-38 directed chimeric antigen receptor constructs

Anti-jagged antibodies and methods of use

B cell maturation antigen binding proteins

Anti-CTLA-4 antibodies and methods of use thereof

CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production

Engineered T cell receptors and immune therapy using the same

Compositions and methods for antibodies targeting EPO

COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS

Systems and methods for targeting cancer cells

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

High affinity B7-H6 antibodies and antibody fragments

Inhibition of SCUBE2, a novel VEGFR2 co-receptor, suppresses tumor angiogenesis

Poly-n-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof

Hydrophilic linkers and ligand-drug conjugates thereof

Plectin-1 binding antibodies and uses thereof

Anti-SIRP-α antibodies and related methods

Compositions and methods for treating pancreatitis and pain with death receptor agonists

Protease-activated T cell bispecific molecules

FULLY HUMAN ANTIBODIES TO BTLA

Antibody drug conjugates

MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF

High-affinity anti-human folate receptor beta antibodies and methods of use

Anti-CD3 antibodies and methods of use

ERBB2-targeting antibody

Humanized antibodies against CD269 (BCMA)

HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47

Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies

MODIFIED CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY

MDR specific antibody

Antibody fab and Fc variants

Compositions and methods for CD20 immunotherapy

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

Compositions and methods for treating cancer with anti-CD19 immunotherapy

Anti-metalloprotease antibody for diagnosis and treatment of cancers

Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins

ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Anti-huLRRC15 antibody drug conjugates and methods for their use

Heterodimeric proteins and methods for producing and purifying them

Method of treating cancer by administering an anti-LGR5 monoclonal antibody

Multimeric bispecific binding molecules specific for CD20 and CD3

Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids

METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS

T-CELL RECEPTOR MIMIC (TCRM) ANTIBODIES

NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER

Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders

Anti-CXCR4 antibodies and antibody-drug conjugates

Multispecific fab fusion proteins and use thereof

Covalent diabodies and uses thereof

Carbohydrate content of CTLA4 molecules

Compositions and methods for producing a composition

Anti-HER2 antibody-drug conjugate and application thereof

Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers

Peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers

Methods and compositions for car T cell therapy

Anti-Sialyl Tn chimeric antigen receptors

CROSS-LINKING POLYPEPTIDE THAT INDUCES APOPTOSIS

Antibodies and related molecules and uses thereof

B7-H4 antibodies and methods of use thereof

Anti-CD33 antibodies and methods of use thereof

ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING

Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof

Methods for treating netosis and neutrophil activation

Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers

Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate

NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE

IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS

Antibodies specific to glycosylated PD-1 and methods of use thereof

Group B adenovirus encoding an anti-TCR-complex antibody or fragment

Anti-neurotensin long fragment antibodies and uses thereof

ANTI-EMP2 THERAPY REDUCES CANCER STEM CELLS

IMMUNOGLOBULIN VARIANTS AND USES THEREOF

Antibodies against human CSF-1R and uses thereof

Compositions and methods for activation of NK cells killing of prostate cancer and breast cancer cells

Humanized Anti-HLA-DR Antibodies

Compositions and methods for immune-mediated cancer therapy

Cancer treatment through RLIP76 partial depletion

Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer

Antibodies specific for DR5 and methods of use

Highly potent antibodies binding to death receptor 4

CD131 binding proteins